MS-1659

MS-1659

A 44-year-old man with active hepatitis B infection is found to have transitional cell carcinoma of the bladder. After a multidisciplinary assessment, it is determined that his cancer is a non-muscle-invasive tumour of intermediate risk. He undergoes a successful transurethral resection of the carcinoma. However, due to his high risk of recurrence, he is being considered for postoperative intravesical chemotherapy or intravesical bacillus Calmette-Guérin (BCG).

Despite having a BCG vaccination scar on his shoulder, he was treated for pulmonary tuberculosis 22 years ago. He has been on antiretroviral therapy for HIV for the past six years.

What is the factor in this patient’s medical history that makes intravesical BCG administration contraindicated?